1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Pharmaids Pharmaceuticals Ltd.

Pharmaids Pharmaceuticals Ltd.

BBSE:PHARMAID
28.29
INR
-0.92
(-3.15%)
-1.24EPS
1.37BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
4.13
5.08
4.95
3.53
1.32
0.54
- -
8.29
3.82
- -
6.43
5.33
7.76
7.17
Basic EPS, GAAP
-1.04
-0.19
-1.17
0.32
-1.13
-0.17
0.03
0.09
0.14
-5.86
-3.51
-3.06
-3.32
-1.29
Free Cash Flow per Basic Share
0.22
0.57
-0.18
0.96
-0.64
-0.11
-0.77
0.39
-0.25
-4.41
-14.74
-7.82
-2.42
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.33
5.04
4.16
4.19
3.06
24.66
8.18
8.27
8.41
10.45
20.43
16.82
13.51
- -
Tangible Book Value per Share
5.33
5.04
4.16
4.19
3.06
24.66
8.18
8.27
8.41
10.45
11.37
7.76
4.6
- -
Basic Weighted Avg Shares
3
3
3
3
3
10
10
10
10
13
23
35
35
35
Sales/Revenue/Turnover
14
17
17
12
4
6
- -
86
39
- -
146
188
274
253
Operating Margin (%)
-36.74
-4.56
-26.24
-6.97
-86.22
-19.23
- -
0.86
3.25
- -
-96.22
-80.6
-56.75
-42.69
Depreciation Expense
1
1
1
1
- -
- -
- -
- -
- -
- -
17
24
20
19
Net Income, GAAP
-4
-1
-4
1
-4
-2
- -
1
1
-76
-80
-108
-117
-46
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-25.21
-3.79
-23.6
9.12
-85.88
-31.6
- -
1.09
3.68
- -
-54.59
-57.28
-42.8
-18.01
Working Capital
11
11
9
10
5
42
4
3
2
162
20
-64
-130
- -
LT Debt
3
1
3
- -
- -
- -
- -
- -
- -
- -
61
331
137
- -
Total Equity
18
17
14
14
10
84
84
85
87
225
705
550
476
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-17.79
-3.71
-25.38
7.71
-31.24
-3.76
0.4
1.1
1.69
-48.54
-16.86
-16.41
-21.91
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
97
- -
LT Borrowings
- -
118
- -
LT Finance Leases
- -
18
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
1,681
976
1,374

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
110
- -
Cash, Cash Equivalents & STI
- -
28
- -
Accounts Receivable, Net
- -
34
- -
Inventories
- -
4
- -
Total Current Liabilities
- -
240
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
97
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
102.05%
67.83%
-13.52%
Free Cash Flow
191.13%
466.44%
-69.09%
Net Income, GAAP
-577.46%
-1,040.14%
8.73%
Sales/Revenue/Turnover
- -
- -
45.5%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
47
52
47
48
188
2026
67
86
54
72
274
2027
41
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.76
-0.73
-0.55
-1.11
-3.06
2026
-1.41
-0.7
-0.7
-0.51
-3.32
2027
0.63
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
B.C Balagangadhara
Full Time Employees
12
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Brigade Rubix Bangalore KA India 560013
IPO Date
Apr 27, 1994
Website
pharmaids.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pharmaids Pharmaceuticals Limited (PHARMAID.BO) manufactures and supplies specialty chemicals, skin care products, hospital care disinfectants, and generic pharmaceuticals; provides contract research and manufacturing services (CRAMS) to the pharma, biotech, agro, and chemical industries; and develops active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and niche products for nutraceutical and veterinary applications. Its specialty chemicals portfolio includes retinol, DL alpha tocopherol, D-pantothenate, cyanocobalamin, pyridoxine HCl, thiamine, nicotinic acid, water-soluble vitamin E, coenzyme Q10, and D-biotin; skin care offerings feature Best Care Hands, hand sanitizers, moisturizing creams, Skinsure Plus, SkinSure Ultra, alcohol gels, and barrier creams; hospital care products encompass Xepi Rub M, Facein Spray, sod hypochlorite, Sanmedin, Strumen G, Strumen Triacid, Facein Eco, Facein Power 256, wipes, and PPE; while generics include Linzomust, Benfoshine, and Duojoint. The company operates primarily in India, targeting domestic and international markets in the pharmaceutical preparations industry with segments in bulk drugs, intermediates, and personal care. Incorporated in 1989 and headquartered in Bengaluru, Karnataka, the company maintains a workforce of approximately 25 employees and conducts operations from its registered office at Brigade Rubix, Peenya Plantation. In January 2024, Pharmaids approved the acquisition of up to 99.94% equity shares in Adita Bio Sys Private Limited via share swap, involving issuance of up to 2,722,258 equity shares on a preferential basis to enhance capabilities in GLP developmental services, drug discovery, laboratory animals, and animal diets, aligning with strategic growth objectives. More recently, in 2025, the company extended a loan of up to INR 60 million to its subsidiary Anugraha Chemicals and launched a mandatory open offer to public shareholders, reflecting ongoing consolidation and financial support for subsidiaries amid robust sales growth, with consolidated net sales reaching Rs 8.61 crore in September 2025, up 64.24% year-over-year.